Health · Greece

Warning on illegal promotion of IV therapies as dietary supplements issued by EOF

4 sourcesFirst reported 13 days agoUpdated 13 days ago

Story Compare

AI summary: catch up in 20 seconds

The Greek National Organization for Medicines (EOF) has issued a warning against the illegal promotion and administration of intravenous therapies presented as dietary supplements.
The EOF highlighted that substances intended for intravenous infusion must be licensed according to pharmaceutical legislation.
Authorities caution that the use of these injectable therapies can pose serious health risks to individuals.
EOF's warning emphasizes the necessity for public awareness regarding the safe use of health treatments.

Generated by AI from the 4 sources below · always verify with the originals

AI summary: catch up in 20 seconds

Summarising the coverage…

Generated by AI from the 4 sources below · always verify with the originals

The full picture

AI-synthesised from 4 sources · no editorial bias

The Hellenic National Organization for Medicines (EOF) has issued a strong warning regarding the illegal promotion and administration of intravenous treatments being presented as dietary supplements. The organization cautioned the public against the use of injectable or intravenously administered solutions that are marketed in this way, as they can pose serious health risks.

According to EOF, substances intended for intravenous injection must comply with licensing regulations outlined in pharmaceutical legislation. The warning highlights the potential dangers associated with these unregulated IV treatments, advising consumers to remain vigilant and avoid such products to protect their health. The EOF's announcement aims to raise awareness and safeguard the public from the risks affiliated with these unauthorized medical offerings.

The full picture

AI-synthesised from 4 sources · no editorial bias

Synthesis generating…

Warning on illegal promotion of IV therapies as dietary supplements issued by EOF

All coverage (4)

Comments · 0 (subscribers)